Concinnity Genetics
Concinnity Genetics is transforming the safety of gene therapies by designing novel control mechanisms using its cutting-edge AI platform and synthetic biology expertise. Founded in 2023, the company emerged from the University of Edinburgh and focuses on creating RNA-based control systems that ensure precise control of gene therapies. With a strong entrepreneurial team and a commitment to innovation, Concinnity aims to address major safety concerns in the biopharmaceutical industry, positioning itself as a leader in the field of gene therapy.
Concinnity Genetics
Concinnity Genetics is transforming the safety of gene therapies by designing novel control mechanisms using its cutting-edge AI platform and synthetic biology expertise. Founded in 2023, the company emerged from the University of Edinburgh and focuses on creating RNA-based control systems that ensure precise control of gene therapies. With a strong entrepreneurial team and a commitment to innovation, Concinnity aims to address major safety concerns in the biopharmaceutical industry, positioning itself as a leader in the field of gene therapy.